Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.

Grade Last Price % Change Price Change
B 18.65 1.30% 0.24
VNDA closed up 1.3 percent on Friday, May 14, 2021, on 71 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical VNDA trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
180 Bullish Setup Bullish Swing Setup 1.30%
Pocket Pivot Bullish Swing Setup 1.30%
Stochastic Reached Overbought Strength 1.30%
Upper Bollinger Band Walk Strength 1.30%
Above Upper BB Strength 1.30%
Older End-of-Day Signals for VNDA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% about 9 hours ago
Possible NR7 about 11 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Down 1% about 14 hours ago
Bullish 180 Entry about 15 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Vanda Pharmaceuticals Inc. Description

Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Alcohol Oncology Chemical Compounds Organic Compounds Chemotherapy Schizophrenia Nervous System Disorders Central Nervous System Disorders Major Depressive Disorder Depressive Disorder Depression Sleep Disorders Nausea Pyridines Treatment Of Major Depressive Disorder Treatment Of Schizophrenia Insomnia Pruritus Sedatives Treatment Of Central Nervous System Disorders Chemotherapy Induced Nausea Fanapt Iloperidone

Is VNDA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 20.51
52 Week Low 9.0
Average Volume 412,982
200-Day Moving Average 13.70
50-Day Moving Average 16.87
20-Day Moving Average 17.21
10-Day Moving Average 17.62
Average True Range 0.62
ADX 19.74
+DI 25.72
-DI 11.57
Chandelier Exit (Long, 3 ATRs ) 16.79
Chandelier Exit (Short, 3 ATRs ) 18.00
Upper Bollinger Band 18.48
Lower Bollinger Band 15.93
Percent B (%b) 1.07
BandWidth 14.79
MACD Line 0.44
MACD Signal Line 0.27
MACD Histogram 0.1726
Fundamentals Value
Market Cap 1.02 Billion
Num Shares 54.7 Million
EPS 0.36
Price-to-Earnings (P/E) Ratio 52.09
Price-to-Sales 2.83
Price-to-Book 1.54
PEG Ratio -2.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.42
Resistance 3 (R3) 19.33 19.00 19.29
Resistance 2 (R2) 19.00 18.80 19.04 19.24
Resistance 1 (R1) 18.82 18.68 18.91 18.91 19.20
Pivot Point 18.49 18.49 18.53 18.53 18.49
Support 1 (S1) 18.31 18.29 18.40 18.40 18.10
Support 2 (S2) 17.98 18.17 18.02 18.06
Support 3 (S3) 17.80 17.98 18.01
Support 4 (S4) 17.89